Search

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce it has been named to the “Brands that Matter” list by Fast Company.

… Tuesday, October 26, 2021 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce it has been named to the “ Brands that Matter ” list by  Fast Company . The inaugural list celebrates 95 global companies and non-profits that have achieved relevance through cultural impact and social engagement

Learn about new insights into endometrial cancer discovered by MSK experts, including why the growing rates of this cancer are even more dangerous for Black women.

… Tuesday, December 19, 2023 The numbers are stark and deeply troubling. Endometrial cancer — which develops in the lining of the uterus (womb) and is sometimes called uterine cancer — is on the rise in the U.S. In 1987, there were 35,000 cases annually. That number has nearly doubled in 2023 to more than

Learn why Black men should be especially mindful of prostate cancer risk.

… Friday, January 17, 2025 Cancer does not discriminate, except when it does.  Prostate cancer  takes a harsher toll on Black men than other American men. Black men are almost 70% more likely than white men to develop prostate cancer in their lifetime and twice as likely to die from the disease, according

Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo®) and ipilimumab (Yervoy®) significantly increased overall survival versus treatment with sunitinib (Sutent®) alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) that were reported online today in the New England Journal of Medicine.

… Wednesday, March 21, 2018 Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo ® ) and ipilimumab (Yervoy ® ) significantly increased overall survival versus treatment with sunitinib (Sutent ® ) alone, according to new findings from researchers

An FDA-approved drug used to treat leukemia can serve as a temporary off switch for CAR T cells, MSK scientists have found.

… Wednesday, July 3, 2019 Summary Researchers at Memorial Sloan Kettering and University Hospital in Würzburg, Germany, have identified a simple way to temporarily switch off CAR T cells with a commonly used drug. The approach could potentially help doctors limit the sometimes-severe side effects of this

According to a new study from Memorial Sloan Kettering published June 24 in Nature Medicine, patients in active cancer treatment who develop COVID-19 infection don’t fare any worse than other hospitalized patients. Researchers say their findings suggest that no one should delay cancer treatment because of concerns about the virus.

… Wednesday, June 24, 2020 Background Mini Kamboj, MD Mini Kamboj, MD Ying Taur, MD, PhD Ying Taur, MD, PhD The characterization of COVID-19 in patients with cancer remains limited in published studies and nationwide surveillance analyses. Reports from China and Italy have raised the possibility that patients

In taking a new approach to finding treatments for hepatocellular carcinoma, MSK scientists have uncovered a potential drug target for this highly aggressive cancer.

… Tuesday, September 30, 2014 Summary In taking a new approach to finding treatments for hepatocellular carcinoma, MSK scientists have uncovered a potential drug target for this highly aggressive cancer. Increasingly, scientists are findings ways to shortcut the search for new cancer therapies. In a recent

A new imaging approach relying on Cerenkov light could sometimes substitute for PET scans and improve diagnostic services in underserved areas.

… Monday, April 11, 2022 Positron emission tomography (PET) is one of the most widely used diagnostic tools in cancer care. PET scans show the location of a tumor, usually based on increased glucose intake, a hallmark of cancer cells. Despite their effectiveness, PET scans can be hard to access in developing

Andrew L. Kung, MD, PhD, has been named the new Chairman of the Department of Pediatrics at Memorial Sloan Kettering Cancer Center (MSK). An accomplished physician, researcher, leader, and mentor, Dr. Kung most recently served as the Chief of the Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation at New York-Presbyterian/Morgan Stanley Children’s Hospital and Columbia University Medical Center (CUMC). Dr. Kung formally assumes his new role as Richard J. O’Reilly, MD, steps down as Chairman after more than 30 years.

… Monday, June 20, 2016 Andrew L. Kung, MD, PhD, has been named the new Chairman of the Department of Pediatrics at Memorial Sloan Kettering Cancer Center (MSK). An accomplished physician, researcher, leader, and mentor, Dr. Kung most recently served as the Chief of the Division of Pediatric Hematology

Learn the differences between physician assistants and nurse practitioners and the important roles they play at Memorial Sloan Kettering.

… Monday, July 6, 2020 At Memorial Sloan Kettering, teamwork is the name of the game. It’s not just one professional taking care of a patient; care teams ensure that every person who walks through the doors is provided for and supported. Vital members of a patient’s care team include physician assistants